Bristol-Myers Squibb’s CEO Peter Dolan and General Counsel Richard Willard resigned Tuesday, spurred by the recommendations of a federal monitor, after the company came perilously close to violating a deferred-prosecution agreement entered last year.

Bristol-Myers director James Cornelius was appointed interim CEO of the New York-based pharmaceutical and health care products company, and Sandra Leung, vice president and corporate secretary, was named interim general counsel. Former FBI director Louis Freeh, now a Bristol-Myers director, was appointed as Leung’s adviser.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]